Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-guided R-CHOP-X vs R-CHOP in DLBCL
NCT05351346Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib, lenalidomide, decitabine in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Started Jun 2022; status: recruiting.
02
Drugs
orelabrutiniblenalidomidedecitabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05351346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351346.